Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 5/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051735 | 1.00 | REN (0.36) | RENCTSLCTSBFNTAFNTB | |
| SCHEMBL7440684 | 0.78 | REN (0.38) | RENCTSLCTSBCTSHCTSK | |
| SCHEMBL7440693 | 0.78 | REN (0.38) | RENCTSLCTSBCTSHCTSK | |
| SCHEMBL30415115 | 0.75 | METAP1 (0.40) | RENCTSLCTSBCTSHCTSK | |
| SCHEMBL17789278 | 0.75 | METAP1 (0.40) | RENCTSLCTSBCTSHCTSK | |
| SCHEMBL10768614 | 0.74 | SLC1A3 (0.37) | METAP2METAP1ALOX5 | |
| SCHEMBL7361728 | 0.74 | SLC1A3 (0.37) | METAP2METAP1ALOX5 | |
| SCHEMBL10354798 | 0.74 | SLC1A3 (0.37) | METAP2METAP1ALOX5 | |
| SCHEMBL7051728 | 0.73 | REN (0.35) | RENCTSLCTSBFNTAFNTB | |
| SCHEMBL9832260 | 0.73 | CTSK (0.36) | RENCTSLCTSBCTSHCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058686-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058686-A1 | Medicament | AGTR2, AGTR1, ACE | REN 5/4885CTSL 311/4885CTSB 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.